Predict your next investment

Antios Therapeutics company logo
HEALTHCARE | Drug Development
antiostherapeutics.com

See what CB Insights has to offer

Founded Year

2018

Stage

Series B | Alive

Total Raised

$125.4M

Last Raised

$96M | 6 mos ago

About Antios Therapeutics

Antios Therapeutics is an Atlanta, GA-based biopharmaceutical company focused on the development of antiviral therapies for unmet medical needs. Antios is advancing a curative regimen for chronic HBV, an unmet global health problem affecting over 250 million people worldwide, and a cause of chronic hepatitis, liver cirrhosis and liver cancer. ATI-2173 is its main oral drug candidate for treating patients infected with Hepatitis B virus (HBV) and potentially Hepatitis D virus (HDV).

Antios Therapeutics Headquarter Location

575 Pharr Road NE Unit 12260

Atlanta, Georgia, 30355,

United States

Latest Antios Therapeutics News

Antios Therapeutics to Participate in H.C. Wainwright 2nd Annual Hepatitis B Virus Conference

Oct 7, 2021

News provided by Share this article Share this article MENDHAM, N.J., Oct. 7, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), today announced that Chief Executive Officer, Gregory Mayes and Chief Medical Officer and Co-Founder, Douglas Mayers, M.D., will participate alongside other leaders in HBV at the H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Virtual Conference. Antios Therapeutics at the H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Virtual Conference Presentation Details: Fireside Chat: Wednesday, October 13, 2021, at 1:30 p.m. ET Presenters: Gregory Mayes, Chief Executive Officer and Douglas Mayers, M.D., Chief Medical Officer and Co-Founder About ATI-2173 ATI-2173, Antios Therapeutics' lead once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate. ATI-2173 has the potential, if approved, to become the cornerstone of a curative HBV regimen. It is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development and its mechanism of action is complementary to other approaches that also seek to achieve a functional cure. ATI-2173 is currently in Phase 2 clinical development. The SAVE-1 (Sustained Anti-Viral Efficacy) trial is an ongoing, double-blind, randomized, placebo-controlled study of 30 patients designed to assess the safety and efficacy of 25 and 50 mg doses of ATI-2173 daily for 90 days in combination with tenofovir disoproxil fumarate (TDF) compared with TDF plus ATI-placebo (control) in chronic HBV-infected subjects. About Antios Therapeutics, Inc. Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Its lead drug candidate ATI-2173 – the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in development – has the potential, if approved, to become the cornerstone of a curative therapeutic regimen for chronic HBV, a major unmet global health problem affecting up to 300 million people worldwide, more than hepatitis C and HIV combined. For more information, please visit www.antiostherapeutics.com . SOURCE Antios Therapeutics

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Antios Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Antios Therapeutics is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

14,138 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,604 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

Antios Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Antios Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.